

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/018,273
				Filing Date	08-07-2002
				First Named Inventor	PERRICAUDET
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	ST99019 - US - PCT
Sheet	1	of	5	RECEIVED JUL 9 2002 TECH CENTER USPTO	

RECEIVED
11-04-2003
151600900

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
bry		EP	0253738		Colin et al.	01-22-1988	1-10	
	•	WO	00/12738		Vigne et al.	03-09-2000	—	
		WO	95/03400		Ketner et al.	02-02-1995	—	
		WO	95/27071		Zhang et al.	10-12-1995	—	
		WO	91/17976		Corr��a et al.	11-28-1991	—	
		WO	93/00928		Bastart et al.	01-21-1993	—	
		WO	93/00929		Bastart et al.	01-21-1993	—	
	•	WO	94/26914		Haddada et al.	11-24-1994	—	
		WO	94/29446		Schweighoffer et al.	12-22-1994	—	
c	•	WO	95/02697		Perricaudet et al.	01-26-1995	—	

Examiner Signature		Date Considered	12/31/87
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031


Approved for use through 10-31-03. GMB 0501-039
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/018,273
Filing Date	08-07-2002			First Named Inventor	PERRICAUDET
Group Art Unit	1614			Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	ST99019 - US - PCT

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	12/13/02
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

O I P E
JUN 3 0 2003

Sheet

3

of

5

Application Number	10/018,273
Filing Date	08-07-2002
First Named Inventor	PERRICAUDET
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	ST99019 - US - PCT

TECH CENTER

JUL 02 2003

1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
hjp		Agnes Paire et al., Characterization of the Rat Thyroid Iodide Transporter Using Anti-Peptide Antibodies, Journ. of Bio. Chem., Vol. 272, No. 29, July 18, 1997, pp. 18425-18249	
		Andre Lieber et al., Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo, Journ. of Virology, Vol. 70, No. 12, Dec. 1996, pp. 8944-8960	
		Valerie Krougiliak et al., Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants, Human Gene Therapy, Vol. 6, Dec. 1995, pages 1575-1586	
		Douglas Hanahan, Heritable Formation Of Pancreatic Beta-cell Tumours in Transgenic Mice Expressing Recombinant Insulin/Simian Virus 40 Oncogenes, Nature, Vol. 315, May 9, 1985, pp. 115-122	
		Ge Dai et al., Cloning And Characterization of the Thyroid Iodide Transporter, Nature, Vol. 379, Feb. 1996, pp. 458-460	
		Goutam Ghosh-Choudhury et al., Human Adenovirus Cloning Vectors Based on Infectious Bacteria Plasmids, Gene, Vol. 50, 1986, pages 161-171	
		Harry R. Maxon et al., Relation Between Effective Radiation Dose and Outcome of Radioiodine Therapy For Thyroid Cancer, NEJM, Vol. 309, No. 16, Oct. 20, 1983	
		J-Y Chu et al., Expression And Activity Of Human Na ⁺ /I ⁻ Symporter In Human Glioma Cells By Adenovirus-mediated Gene Delivery (Abstract XP2155151), Gene Therapy, Vol. 7, May, 2000, pages 740-749	
		J. Chroboczek et al., The Sequence Of The Genome of Adenovirus Type 5 and Its Comparison With the Genome of Adenovirus Type 2, Virology, Volume 186, 1992, pages 1-13	
		Joel Crouzet et al., Recombinational Construction in Escherichia Coli of Infectious Adenoviral Genomes, Proc. Natl. Acad. Sci, USA, Vol 94, Feb. 1997, pages 1414-1419	
		John Nemunaitis et al., Phase I Trial of Interferon- γ (IFN- γ) Retroviral Vector Administered Intratumorally To Patients With Metastatic Melanoma, Cancer Gene Therapy, Vol. 6, No. 4, 1999, pages 322-330	

Examiner Signature

Date Considered

12/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number 10/018,273

Filing Date 08-07-2002

First Named Inventor PERRICAUDET

Group Art Unit 1614

Examiner Name Unknown

Attorney Docket Number ST99019 - US - PCT

RECEIVED

JUL 02 2003
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
hp		MANDELL R, Gene Therapy of Cancer by Retroviral Transfer and Expression of the Rate Sodium/Iodide Symporter (NIS), 88th Annual Meeting of the American Association for Cancer Research, San Diego, CA, USA; April 12-16, 1997, Vol. 38, 1997, page 381
		MANDELL Robert B, Radiosotope Concentrator Gene Therapy Using the Sodium/Iodine Symporter Gene, Cancer Research, Feb. 1, 1999, Vol. 59, No. 3 pages 661-668
		Massimo Levero et al., Defective And Nondefective Adenovirus Vectors For Expressing Foreign Genes In Vitro and In Vivo, Gene, Vol. 101, 1991, pp. 195-202
		Michael Boshart et al., A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus, Cell, Vol. 41, June 1985, pages 521-530
		Orlie Levy et al., N-linked Glycosylation of the Thyroid Na+/I- Symporter (NIS), Journ. of Bio. Chem, Vol. 273, August 28, 1998, pp. 22657-22663
		P.A. Smanik et al., Cloning of the Human Sodium Iodide Symporter, Biochemical and Biophysical Research Communications, 1996, pages 339-345
		Patrice Yeh et al., Efficient Dual Transcomplementation of Adenovirus E1 and E4 Regions From a 293-Derived Cell Line Expressing a Minimal E4 Functional Unit, Journ. of Virology, Vol. 70, No. 1, Jan. 1996, pp. 559-565
		Peter C. Van Der Vliet et al., Thermolabile DNA Binding Proteins from Cells Infected With a Temperature-Sensitive Mutant of Adenovirus Defective In Viral DNA Synthesis, Journ. of Virology, Vol. 15, No. 2, Feb. 1975, pages 348-354
		R. M. Myers, Human STSs, Unpublished, 1997, pages 1-2
		Toyoshi Endo et al., Thyroid Transcription Factor-1 Activates the Promoter Activity of Rat Thyroid Na+/I- Symporter Gene, Molecular Endocrinology Vol. 11, 1997, pages 1747-1755
		Robin J. Parks et al., A Helper-Dependent Adenovirus Vector System: Removal of Helper Virus by Cre-mediated Excision of the Viral Packaging Signal, Proc. Natl. Acad. Sci., USA, Vol. 93, Nov. 1996, pages 13565-13570

Examiner Signature

Date Considered

12/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Approved for use through 10/31/93. GMB 055-1-055
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Collection of information unless it contains a valid OMB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	5	of	5	Application Number	10/018,273
				Filing Date	08-07-2002
				First Named Inventor	PERRICAUDET
				Group Art Unit	1614
				Examiner Name	Unknown
				Attorney Docket Number	ST99019 - US - PCT

JUN 3 0 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

'Shee

5

5

Complete if Known

Application Number 10/018,273

Filing Date 08-07-2002

First Named Inventor


Group Art Unit

Examiner Name	Unknown
---------------	---------

Attorney Docket Number ST99019 - US - PCT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Stuart J. Weiss et al., Iodide Transport in a Continuous Line of Cultured Cells from Rat Thyroid, Endocrinology, Vol. 114, No. 4, 1984, pages 1090-1098	

Examiner Signature		Date Considered	12/13/03
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.